Compare BSY & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSY | IONS |
|---|---|---|
| Founded | 1984 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.3B |
| IPO Year | 2020 | 1991 |
| Metric | BSY | IONS |
|---|---|---|
| Price | $42.02 | $82.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | $56.73 | ★ $80.71 |
| AVG Volume (30 Days) | 2.2M | ★ 3.2M |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $1,460,019,000.00 | $966,957,000.00 |
| Revenue This Year | $11.15 | $27.96 |
| Revenue Next Year | $10.37 | $2.33 |
| P/E Ratio | $50.69 | ★ N/A |
| Revenue Growth | 11.12 | ★ 20.41 |
| 52 Week Low | $36.51 | $23.95 |
| 52 Week High | $59.25 | $82.95 |
| Indicator | BSY | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 71.14 |
| Support Level | $40.80 | $71.83 |
| Resistance Level | $42.02 | $74.50 |
| Average True Range (ATR) | 1.25 | 3.30 |
| MACD | 0.01 | 0.85 |
| Stochastic Oscillator | 32.10 | 97.05 |
Bentley Systems is a software vendor that caters to engineers, architects, constructors, and geospatial professionals by enabling design, modeling, simulation, project management, and data management of infrastructure assets. The firm delivers solutions via the cloud, desktop, and hybrid environments. While Bentley is relatively small in comparison with peers like Autodesk, it shines in core specialty areas, like bridge or rail design, as opposed to being more broad-based in its applications. Bentley's largest end market is the public works and utilities sector, which represents approximately two thirds of revenue.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.